Mirtazapin Neuraxpharm (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Neuraxpharm, is a Noradrenergic and specific serotonergic antidepressant (NaSSA) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients and works by modulating norepinephrine and serotonin pathways to improve mood, sleep and appetite.

GNH USA supplies Mirtazapin Neuraxpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Mirtazapine is a NaSSA antidepressant used primarily in the management of depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves overall functioning.

Mirtazapine may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal ideation or behavior - Severe hypotension - Hepatic dysfunction or failure

When prescribing Mirtazapine, clinicians should consider several safety precautions.

- Pregnancy: use only if potential benefit justifies the potential risk to the fetus. - Breastfeeding: safety not established; consider alternative therapy. - Elderly: monitor for excessive sedation and increased fall risk. - Concomitant CNS depressants: may enhance sedative effects. - History of bipolar disorder: risk of mood switching to mania. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis; avoid co‑administration. - Carbamazepine: strong enzyme inducer that reduces mirtazapine plasma levels. - Fluoxetine: CYP2D6 inhibition may increase mirtazapine concentrations.

Moderate Interactions (Monitor Closely): - Alcohol: additive central nervous system depression. - Other serotonergic agents (e.g., tramadol, linezolid): potential serotonin syndrome. - Warfarin: may alter INR; monitor coagulation parameters.